Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rita S Axelrod

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Seminars in Oncology|December 10, 2009
Introduction: women and lung cancerRita S Axelrod
Cancer|January 20, 2011
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)Athanassios Argiris, Musie Ghebremichael, Barbara Burtness, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2015
Reply to D. Adkins et alRita S Axelrod, Eric Sherman, Adam Garden, et al.
American Journal of Clinical Oncology|July 9, 2016
Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck CancerPeter H Ahn, Mitchell Machtay, Pramila R Anne, et al.
Seminars in Radiation Oncology|March 28, 2002
Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapyMaria Werner-Wasik, Rita S Axelrod, David P Friedland, et al.
International Journal of Radiation Oncology, Biology, Physics|January 17, 2012
Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignanciesGregory J Kubicek, Rita S Axelrod, Mitchell Machtay, et al.
Cancer Chemotherapy and Pharmacology|November 30, 2013
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancerTaofeek K Owonikoko, Joseph Aisner, Xin Victoria Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|March 13, 2013
The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801Yaacov Richard Lawrence, Rebecca Paulus, Corey Langer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522K Kian Ang, Qiang Zhang, David I Rosenthal, et al.
International Journal of Radiation Oncology, Biology, Physics|December 22, 2022
Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck CancerJimmy J Caudell, Pedro A Torres-Saavedra, David I Rosenthal, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Seminars in Oncology|December 10, 2009
Introduction: women and lung cancerRita S Axelrod
Cancer|January 20, 2011
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)Athanassios Argiris, Musie Ghebremichael, Barbara Burtness, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2015
Reply to D. Adkins et alRita S Axelrod, Eric Sherman, Adam Garden, et al.
American Journal of Clinical Oncology|July 9, 2016
Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck CancerPeter H Ahn, Mitchell Machtay, Pramila R Anne, et al.
Seminars in Radiation Oncology|March 28, 2002
Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapyMaria Werner-Wasik, Rita S Axelrod, David P Friedland, et al.
International Journal of Radiation Oncology, Biology, Physics|January 17, 2012
Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignanciesGregory J Kubicek, Rita S Axelrod, Mitchell Machtay, et al.
Cancer Chemotherapy and Pharmacology|November 30, 2013
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancerTaofeek K Owonikoko, Joseph Aisner, Xin Victoria Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|March 13, 2013
The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801Yaacov Richard Lawrence, Rebecca Paulus, Corey Langer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522K Kian Ang, Qiang Zhang, David I Rosenthal, et al.
International Journal of Radiation Oncology, Biology, Physics|December 22, 2022
Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck CancerJimmy J Caudell, Pedro A Torres-Saavedra, David I Rosenthal, et al.
Pageof 2